Nancy E. Davidson

Nancy E. Davidson's AcademicInfluence.com Rankings

Nancy E. Davidson

Philosophy

#4165

World Rank

#6576

Historical Rank

Logic

#1687

World Rank

#2502

Historical Rank

philosophy Degrees

Nancy E. Davidson

Biology

#5360

World Rank

#7818

Historical Rank

Immunology

#248

World Rank

#258

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Nancy E. Davidson's Degrees

Doctorate Medicine Harvard University

Why Is Nancy E. Davidson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Nancy E. Davidson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. (2005) (5306)
Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. (2007) (2993)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. (1993) (1992)
Estrogen carcinogenesis in breast cancer. (2006) (1729)
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. (1995) (1490)
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. (2003) (1462)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. (2010) (1260)
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon (1994) (1253)
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer (2003) (1091)
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. (2005) (1044)
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. (2014) (1004)
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. (2004) (880)
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. (1995) (876)
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. (2014) (741)
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. (2015) (722)
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. (2011) (685)
Weekly paclitaxel in the adjuvant treatment of breast cancer. (2008) (673)
Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. (2014) (671)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. (2008) (611)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (2015) (550)
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. (2006) (527)
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. (2010) (524)
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. (1994) (516)
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. (2013) (513)
Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. (1993) (511)
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. (2008) (507)
A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast (2013) (476)
Adjuvant ovarian suppression in premenopausal breast cancer. (2015) (467)
Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. (1988) (459)
Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. (2020) (457)
Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. (1991) (448)
Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. (1999) (437)
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. (2016) (435)
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. (2002) (392)
Exercise manages fatigue during breast cancer treatment: A randomized controlled trial (2005) (378)
Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells (2001) (359)
Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. (2001) (356)
Anticancer activities of novel chalcone and bis-chalcone derivatives. (2006) (349)
Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR (2001) (348)
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer (2018) (348)
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers (2014) (344)
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. (2006) (344)
Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. (1995) (328)
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. (2008) (326)
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. (2014) (324)
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. (2000) (306)
Sulforaphane induces cell type–specific apoptosis in human breast cancer cell lines (2007) (305)
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. (2019) (294)
Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. (2007) (293)
Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. (1996) (290)
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. (2013) (283)
Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. (1996) (280)
Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. (2003) (279)
Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. (1987) (278)
American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. (1999) (258)
Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. (1987) (256)
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. (2001) (253)
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. (2011) (251)
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. (2000) (240)
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. (2004) (238)
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer (2007) (232)
Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. (1994) (230)
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. (2008) (230)
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. (2016) (228)
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2014) (225)
Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. (2015) (223)
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. (2010) (222)
DNA methylation in breast cancer. (2001) (221)
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). (2005) (215)
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. (2009) (214)
The biology of breast carcinoma (2003) (210)
MCF-7 cells--changing the course of breast cancer research and care for 45 years. (2015) (199)
Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer (2012) (197)
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
Mapping of ER Gene CpG Island Methylation by Methylation-specific Polymerase Chain Reaction (1998) (197)
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. (2006) (196)
The Loss of Estrogen and Progesterone Receptor Gene Expression in Human Breast Cancer (2004) (193)
Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles (2012) (190)
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. (2018) (184)
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. (2008) (179)
Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. (1994) (179)
Modulation of aflatoxin metabolism, aflatoxin-N7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. (1986) (176)
Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. (2005) (176)
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. (2009) (175)
The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. (1996) (169)
Autocrine and paracrine growth regulation of human breast cancer. (1986) (169)
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy (2013) (166)
Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. (2005) (165)
High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. (1991) (164)
Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. (2009) (164)
Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients (2015) (163)
A Novel Histone Deacetylase Inhibitor, Scriptaid, Enhances Expression of Functional Estrogen Receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine (2003) (162)
Inhibition of Histone Deacetylases Promotes Ubiquitin-Dependent Proteasomal Degradation of DNA Methyltransferase 1 in Human Breast Cancer Cells (2008) (158)
Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases (2008) (157)
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. (2015) (155)
Role of Estrogen Receptor Gene Demethylation and DNA Methyltransferase·DNA Adduct Formation in 5-Aza-2′deoxycytidine-induced Cytotoxicity In Human Breast Cancer Cells* (1997) (155)
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation (2007) (149)
Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. (2014) (141)
Estrogen Replacement Therapy in Breast Cancer Survivors: A Time for Change (1994) (140)
Mapping of ER gene CpG island methylation-specific polymerase chain reaction. (1998) (140)
Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. (1998) (136)
A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100 (2006) (135)
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. (2007) (135)
Increased Protein Stability Causes DNA Methyltransferase 1 Dysregulation in Breast Cancer* (2005) (131)
NCCN Practice Guidelines for Breast Cancer. (2000) (129)
Transforming Cancer Prevention through Precision Medicine and Immune-oncology (2016) (128)
Future cancer research priorities in the USA: a Lancet Oncology Commission. (2017) (125)
Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. (1997) (125)
Epigenetics in breast cancer: what's new? (2011) (125)
Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells (2010) (125)
Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases (2017) (121)
Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal Fluid (2006) (118)
Spermine Oxidase SMO(PAOh1), Not N1-Acetylpolyamine Oxidase PAO, Is the Primary Source of Cytotoxic H2O2 in Polyamine Analogue-treated Human Breast Cancer Cell Lines* (2005) (115)
Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. (1992) (113)
Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells (2012) (113)
Inhibition of Histone Lysine-specific Demethylase 1 Elicits Breast Tumor Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade (2018) (112)
Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. (2014) (112)
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. (2013) (111)
The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway (2011) (110)
Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. (1995) (109)
Fenugreek: A naturally occurring edible spice as an anticancer agent (2009) (106)
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models (2017) (101)
Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. (2013) (100)
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study (2016) (99)
Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. (1995) (99)
Specific Inhibition of DNMT1 by Antisense Oligonucleotides Induces Re-expression of Estrogen Receptor a (ER) in ER-negative Human Breast Cancer Cell Lines (2003) (95)
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. (2004) (93)
Comparison of Paclitaxel-, 5-Fluoro-2′-deoxyuridine-, and Epidermal Growth Factor (EGF)-induced Apoptosis (1999) (92)
A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. (2003) (92)
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial (2006) (92)
Role of DNA Methylation and Histone Acetylation in Steroid Receptor Expression in Breast Cancer (2001) (91)
Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199 (2015) (91)
Transcriptional control of glutathione S-transferase gene expression by the chemoprotective agent 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz) in rat liver. (1990) (91)
Estrogen Receptor α Mediates Breast Cancer Cell Resistance to Paclitaxel through Inhibition of Apoptotic Cell Death (2007) (90)
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. (2012) (88)
Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells (2012) (88)
Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. (1999) (86)
Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. (2012) (86)
Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. (1994) (85)
Induction of programmed cell death in human breast cancer cells by an unsymmetrically alkylated polyamine analogue. (1995) (84)
Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. (1994) (82)
Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer (2010) (81)
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021) (81)
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. (2008) (79)
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. (2008) (79)
Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial. (2009) (78)
Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. (2010) (77)
The follow-up of breast cancer. (2003) (77)
Epigenetic Regulation as a New Target for Breast Cancer Therapy (2007) (77)
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. (2018) (76)
Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. (1993) (75)
Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468. (1992) (75)
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. (2012) (75)
Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. (2019) (74)
Transcriptional control of thymidine kinase gene expression by estrogen and antiestrogens in MCF-7 human breast cancer cells. (1986) (73)
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. (2013) (73)
Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer (2014) (72)
A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells. (2003) (72)
Molecular mechanisms of polyamine analogs in cancer cells. (2005) (72)
Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage (2015) (71)
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer (2012) (71)
Functional Interaction of Histone Deacetylase 5 (HDAC5) and Lysine-specific Demethylase 1 (LSD1) Promotes Breast Cancer Progression (2016) (71)
A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer (2008) (71)
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study (2012) (71)
E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer (2005) (71)
Trastuzumab in breast cancer. (2004) (70)
Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. (1995) (69)
Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. (2007) (68)
A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer (2014) (67)
The search for ESR1 mutations in breast cancer (2013) (65)
Polyamine analogue induction of programmed cell death in human lung tumor cells. (1996) (64)
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. (2008) (63)
Growth inhibition of hormone-responsive and -resistant human breast cancer cells in culture by N1, N12-bis(ethyl)spermine. (1993) (63)
Adjuvant endocrine therapy for premenopausal women with early breast cancer (2007) (63)
Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells (2009) (63)
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. (2011) (63)
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer (2018) (62)
Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells. (2000) (61)
Hormonal therapy in breast cancer: A model disease for the personalization of cancer care (2012) (60)
Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells. (1996) (59)
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer (2012) (58)
Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure (2016) (58)
TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer (2015) (58)
Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells (2014) (58)
Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial (2005) (58)
American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. (2011) (58)
Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products. (1986) (58)
Detection and Quantification of the Evolution Dynamics of Apoptosis Using the PET Voltage Sensor 18F-Fluorobenzyl Triphenyl Phosphonium (2009) (58)
Practical Approach to Triple-Negative Breast Cancer. (2017) (56)
The role of estrogens in growth regulation of breast cancer. (1989) (56)
A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer (2017) (55)
Methyl-group dietary intake and risk of breast cancer among African-American women: a case–control study by methylation status of the estrogen receptor alpha genes (2003) (55)
Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer (2016) (54)
Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. (2002) (54)
Pharmacogenetics in the treatment of breast cancer (2004) (54)
Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. (1996) (54)
Biology of breast cancer (1991) (53)
Improved clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA oncology program uniting pediatric and medical oncology divisions (2012) (53)
Primary systemic therapy in operable breast cancer. (2000) (52)
v-rasH induces non-small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line. (1990) (51)
Update: NCCN practice guidelines for the treatment of breast cancer. National Comprehensive Cancer Network. (1999) (50)
The molecular landscape of premenopausal breast cancer (2015) (50)
PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? (2007) (49)
Estrogen Replacement Therapy in Breast Cancer Survivors-Reply (1995) (48)
Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. (1994) (48)
Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial (2013) (47)
Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells (1999) (46)
Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. (2001) (46)
Demethylation of the progesterone receptor CpG island is not required for progesterone receptor gene expression (1998) (46)
Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831 (2012) (46)
Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies (2018) (46)
WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines (2016) (45)
Screening for therapeutic targets of vorinostat by SILAC‐based proteomic analysis in human breast cancer cells (2010) (44)
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer (2019) (44)
Ovarian ablation as adjuvant therapy for breast cancer. (2001) (44)
What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? (2004) (44)
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‐positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831 (2013) (44)
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary. (2018) (43)
Multiparametric and Multinuclear Magnetic Resonance Imaging of Human Breast Cancer: Current Applications (2004) (43)
Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. (2018) (43)
Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. (2010) (42)
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100 (2014) (41)
HDAC5–LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells (2018) (41)
Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth (2017) (41)
Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors (2014) (41)
Ovarian ablation as adjuvant therapy for breast cancer. (2001) (40)
Protein Phosphatase 2A Regulates Estrogen Receptor α (ER) Expression through Modulation of ER mRNA Stability* (2005) (40)
The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines (2010) (40)
A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. (2004) (39)
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials (2022) (39)
Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198) (2015) (39)
Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. (1990) (39)
Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts. (1991) (39)
Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199 (2007) (38)
S4-6: A Quantitative Multigene RT-PCR Assay for Predicting Recurrence Risk after Surgical Excision Alone without Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective Validation Study of the DCIS Score from ECOG E5194. (2011) (38)
Regulation of Estrogen Receptor α Function in Breast Cancer (1997) (38)
Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells (2012) (38)
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. (2020) (37)
Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells. (2013) (37)
Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China (1997) (37)
Epigenetic regulation of protein phosphatase 2A (PP2A), Lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells (2004) (36)
Regulation of polyamine analogue cytotoxicity by c-Jun in human MDA-MB-435 cancer cells. (2004) (36)
Polyamine Analogues Down-regulate Estrogen Receptor α Expression in Human Breast Cancer Cells* (2006) (36)
Integrated Proteomic and Metabolic Analysis of Breast Cancer Progression (2013) (35)
Novel Insight into KLF4 Proteolytic Regulation in Estrogen Receptor Signaling and Breast Carcinogenesis* (2012) (34)
A "bone" fide predictor of metastasis? Predicting breast cancer metastasis to bone. (2006) (33)
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative (2021) (33)
AACR Cancer Progress Report 2016 (2016) (32)
Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial. (2009) (32)
Of Snail, mice, and women. (2005) (32)
Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer. (1993) (32)
Hormone-replacement therapy--breast versus heart versus bone. (1995) (32)
Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. (1995) (32)
Effects of the polyamine analogues N1-ethyl-N11-((cyclopropyl)methyl)-4,8-diazaundecane and N1-ethylN-11-((cycloheptyl)methyl)-4,8-diazaundecane in human prostate cancer cells. (2000) (32)
Disease Subtype–Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A (2017) (31)
Hepsulfam sensitivity in human breast cancer cell lines: the role of glutathione and glutathione S-transferase in resistance. (1992) (31)
RETRACTED ARTICLE: Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy (2013) (30)
Gene expression profiling of breast cancer. (2008) (29)
Adjuvant hormonal therapy for premenopausal women with breast cancer. (2003) (28)
Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole (2011) (28)
Sometimes a great notion--an assessment of neoadjuvant systemic therapy for breast cancer. (2005) (28)
Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. (2013) (28)
Inhibition of histone deacetylases. (2011) (27)
Monoclonal antibody cocktail as an enrichment tool for acetylome analysis. (2011) (27)
of disease Estrogen Carcinogenesis in Breast Cancer (2006) (27)
Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer (2013) (27)
A Pilot Phase II Trial of Valspodar Modulation of Multidrug Resistance to Paclitaxel in the Treatment of Metastatic Carcinoma of the Breast (E1195): A Trial of the Eastern Cooperative Oncology Group (2006) (26)
Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198 (2010) (26)
Effect of hepatocarcinogens on the binding of glucocorticoid-receptor complex in rat liver nuclei. (1976) (26)
Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms. (2014) (26)
The Reliability of Nipple Aspirate and Ductal Lavage in Women at Increased Risk for Breast Cancer—a Potential Tool for Breast Cancer Risk Assessment and Biomarker Evaluation (2007) (26)
Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. (2016) (26)
AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health (2018) (26)
Apoptosis in the mammary gland and breast cancer (1998) (25)
Tamoxifen--panacea or Pandora's box? (1992) (25)
A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer (2015) (25)
Ovarian ablation as treatment for young women with breast cancer. (1994) (25)
Programmed cell death in human breast cancer cells. (1996) (25)
Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer (2009) (25)
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial (2014) (25)
Epigenetic reprogramming in breast cancer: From new targets to new therapies (2014) (25)
Regulation of estrogen receptor alpha function in breast cancer. (1997) (24)
Induction of spermidine/spermine N1-acetyltransferase in breast cancer tissues treated with the polyamine analogue N1,N11-diethylnorspermine (2004) (24)
Adjuvant endocrine therapy for premenopausal women with breast cancer. (2009) (23)
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. (2013) (23)
Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells (2006) (23)
Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood (2018) (22)
Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 (2013) (22)
Environmental estrogens and breast cancer risk (1998) (22)
Adjuvant systemic therapy in women with early-stage breast cancer at high risk for relapse. (1992) (22)
Epigenetics meets estrogen receptor: regulation of estrogen receptor by direct lysine methylation. (2009) (21)
RETRACTED ARTICLE: Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy (2014) (21)
Expertise vs evidence in assessment of breast biopsies: an atypical science. (2015) (21)
Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression. (2017) (21)
Induction of jun Gene Family Members by Transforming Growth Factor α but not 17β-Estradiol in Human Breast Cancer Cells (1993) (21)
Aflatoxin inhibition of glucocorticoid finding capacity of rat liver nuclei. (1976) (20)
Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells (2000) (20)
Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer (2011) (20)
Combined endocrine therapy for breast cancer--new life for an old idea? (2000) (20)
The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831 (2015) (19)
Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility. (2005) (19)
Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. (2006) (19)
Good news about oral contraceptives. (2002) (19)
Breast cancer biology blossoms in the clinic (1998) (19)
Chemoprotection by inducers of electrophile detoxication enzymes. (1993) (18)
Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. (2016) (18)
Developing in vitro models of human ductal carcinoma in situ from primary tissue explants (2015) (18)
Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial. (2004) (18)
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer (2011) (18)
Genotypic characterization of phenotypically defined triple-negative breast cancer. (2009) (18)
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update (2021) (18)
Out of the courtroom and into the clinic. (1992) (18)
HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. (2004) (17)
Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of Igf1r That Persists Long after Parturition (2015) (17)
Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs (2015) (17)
Role of p53/p21Waf1/Cip1 in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cells (2005) (17)
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update (2022) (16)
Adjuvant endocrine therapy for breast cancer: how long is long enough? (2013) (16)
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. (2020) (16)
Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update (2022) (16)
Stimulation of breast cancer with estrogens: how much clinical value? (1987) (16)
A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer. (2011) (16)
Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts. (1996) (16)
The silent estrogen receptor--can we make it speak? (2009) (16)
Tobacco control: reducing cancer incidence and saving lives. American Society of Clinical Oncology. (1996) (16)
Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation (2021) (16)
A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC). (2011) (15)
Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100). (2009) (15)
Epigenetic Biomarkers and Breast Cancer: Cause for Optimism (2006) (15)
Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. (2015) (15)
A Phase II Study of the Polyamine Analog N 1 , N 11-Diethylnorspermine ( DENSpm ) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer (2003) (15)
Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study. (2012) (15)
Human Cancers Associated with Aberrant DNA Methylation in All Common Gene Is Frequently CDKN 2 / p 16 / MTS 1 Inactivation of the Updated (2006) (15)
Apoptosis and Breast Cancer (1999) (15)
TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer (2012) (15)
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer (2013) (15)
African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. (2009) (15)
Pesticides and breast cancer: fact or fad? (1997) (15)
A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer (2007) (14)
Adjuvant hormonal therapy for premenopausal women with breast cancer. (2006) (14)
Independent review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherapy for metastatic breast cancer (MBC) (2008) (14)
Transferases S Role of Induction of Glutathione Ethoxyquin : Formation , and Hepatic Tumorigenesis in Rats Fed-guanine 7 N Modulation of Aflatoxin Metabolism , Aflatoxin-Updated Version (2006) (13)
Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial. (2016) (13)
Aromatase inhibitors for breast cancer (2007) (13)
Polyamine analogues down-regulate estrogen receptor alpha expression in human breast cancer cells. (2006) (13)
Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: a phase 2 study. (2000) (13)
Hematopoietic growth factors: Personalization of risks and benefits (2012) (13)
What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer? (2009) (13)
Protein Phosphatase 2A (PP2A) regulates Estrogen Receptor Alpha (ER) expression through modulation of ER mRNA stability. (2005) (13)
Abstract S1-07: Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 (2013) (13)
Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma (2020) (12)
Dose intensity for breast cancer. (2001) (12)
Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. (2009) (12)
Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer (MBC): preliminary results of the Eastern Cooperative Oncology Group Trial E3198 (Abstract) (2003) (12)
Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence (2009) (12)
Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression (2017) (11)
The regulation of estrogen receptor expression and function in human breast cancer. (1998) (11)
New Strategies in Metastatic Hormone Receptor–Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies (2016) (11)
Abstract 4666: A phase 2 study investigating the safety, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) andentinostat (MS-275) in patients with triple-negative advanced breast cancer. (2013) (11)
Chemoprevention for breast cancer: overcoming barriers to treatment. (2012) (10)
"MAPping" the course of chemoprevention in breast cancer. (2011) (10)
Improving Goal Concordant Care Among 10 Leading Academic U.S. Cancer Hospitals: A Collaboration of the Alliance of Dedicated Cancer Centers (2021) (10)
Breast cancer consensus meetings: vive la difference? (2002) (10)
Abstract S3-08: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial (2015) (10)
Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. (2007) (10)
Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193. (2005) (10)
Role of p53/p21(Waf1/Cip1) in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cells. (2005) (10)
Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. (2011) (9)
Final Results of ECOG1100: A phase I/II study of combined blockade of the ErbB receptor network in patients with HER2- overexpressing metastatic breast cancer (MBC) (2007) (9)
Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer. (2006) (9)
Use of SERMs for the Adjuvant Therapy of Early‐Stage Breast Cancer (2001) (9)
Recurrent hyperactive ESR 1 fusion proteins in endocrine therapy-resistant breast cancer (2018) (9)
Biology of breast cancer and its clinical implications (1992) (9)
Silencing estrogen receptor alpha in breast cancer cells. (2006) (8)
Multiparametric Magnetic Resonance Imaging, Spectroscopy and Multinuclear ( 23 Na) Imaging Monitoring of Preoperative Chemotherapy for Locally Advanced Breast Cancer (2012) (8)
Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial. (2011) (8)
Advances in Brief Aberrant Methylation of the Estrogen Receptor and E-Cadherin 5 * CpG Islands Increases with Malignant Progression in Human Breast Cancer 1 (2000) (8)
Image-based risk score to predict recurrence of ER+ breast cancer in ECOG-ACRIN Cancer Research Group E2197. (2018) (8)
10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features. (2012) (8)
Can Circulating Tumor Cells Predict Resistance in Metastatic Breast Cancer? (2015) (8)
Abstract S5-4: EGFR expression measured by quantitative immunofluorescense is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial. (2012) (8)
CT evaluation of breast cancer: spectrum of disease. (1993) (7)
Protein kinase C and breast cancer. (1996) (7)
Obesity and Breast Cancer: A Multipartite Connection (2013) (7)
Combined therapy in advanced breast cancer. (1985) (7)
The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814 (2016) (7)
The Importance of Cytologic Intrarater and Interrater Reproducibility: the Case of Ductal Lavage (2006) (7)
Author reply (7)
Aromatase inhibitors as adjuvant therapy in breast cancer. (2003) (7)
Patterns of recurrence by sequence of chemotherapy and radiotherapy in early stage breast cancer (2003) (7)
A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer (1999) (7)
Targeting tumorigenicity of breast cancer stem-like cells using combination epigenetic therapy: something old and something new. (2016) (7)
Apoptosis in hormone-responsive malignancies. (1997) (7)
OT3-01-06: A Phase 2 Study Investigating the Safety, Efficacy and Surrogate Biomarkers of Response of 5-Azacitidine (5-AZA) and Entinostat (MS-275) in Patients with Advanced Breast Cancer. (2011) (7)
c-MYC amplification and correlation with patient outcome in early stage HER2+ breast cancer from the NCCTG adjuvant intergroup trial N9831. (2009) (7)
Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196. (2006) (7)
Adjuvant endocrine therapy for breast cancer: don't ditch the switch! (2011) (7)
Biomarkers and surrogacy: relevance to chemoprevention. (2001) (7)
Early operable breast cancer (2000) (6)
Is hormone replacement therapy a risk? (1996) (6)
Breast cancer: The 21-gene recurrence score — biology remains at the forefront (2016) (6)
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis (2022) (6)
HER2 concordance between central laboratory immunohistochemistry and quantitative reverse transcription polymerase chain reaction in Intergroup Trial E2197 (2008) (6)
Case records of the Massachusetts General Hospital. Case 35-2005. A 56-year-old woman with breast cancer and isolated tumor cells in a sentinel lymph node. (2005) (6)
Abstract S3-03: Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer (2015) (6)
Silencing estrogen receptor α in breast cancer cells (2006) (6)
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. (2003) (6)
Pilot trial of paclitaxel-herceptin adjuvant therapy for early stage breast cancer (E2198) (2001) (6)
Is it time to ReSET the standard for estrogen receptor testing in breast cancer? (2010) (6)
Should we embrace or ablate our urge to (ovarian) suppress? (2014) (6)
Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer (2004) (6)
Ongoing US cooperative group trials using taxanes in the adjuvant setting. (2002) (6)
Induction of jun gene family members by transforming growth factor alpha but not 17 beta-estradiol in human breast cancer cells. (1993) (6)
The maturation of medical oncology. (2007) (5)
Postoperative endocrine therapy for invasive breast cancer. (2009) (5)
Do the ASCO/CAP 2007 HER2 Testing Guidelines Improve Prediction of Benefit to Adjuvant Trastuzumab?: Data from North Central Cancer Treatment Group N9831 Adjuvant Trial. (2009) (5)
Menstrual effects on surgical treatment for breast cancer. (1993) (5)
Ki67 Assessment in Breast Cancer: Are We There yet? (2020) (5)
Using mice to treat (wo)men: mining genetic changes in patient xenografts to attack breast cancer. (2013) (5)
Prognostic/Predictive immunohistochemistry assays for estrogen receptor-positive breast cancer: back to the future? (2012) (5)
Primary chemotherapy for locally advanced breast cancer using film as a novel regimen (1998) (5)
Treatment for breast cancer: is time really of the essence? (2013) (5)
The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831. (2013) (5)
The American Society of Clinical Oncology Cancer Foundation Grants Program: a 25-year report and a look toward the future. (2010) (5)
Breast cancer in 2013: Genomics, drug approval, and optimal treatment duration (2014) (5)
Breast cancer metastatic to the choroid. (1998) (5)
Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. (2016) (4)
The use of anthracyclines and taxanes for adjuvant therapy of breast cancer (2001) (4)
GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer. (2009) (4)
Funding for clinical (patient-oriented) oncology research: current status and recommendations for improvement. American Society of Clinical Oncology. (1996) (4)
Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome (2013) (4)
P7 antigen expression in human breast cancer. (2003) (4)
S35 Adjuvant therapies for premenopausal women with endocrine-responsive disease (2009) (4)
Optimal adjuvant endocrine therapy for breast cancer. (2021) (4)
Radiotherapy concurrent with trastuzumab is well tolerated in the adjuvant treatment of women with HER2-positive breast cancer: cardiac safety data from the NCCTG N9831 study (2006) (4)
HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors? (2016) (4)
Black Race Is Associated with a Worse Outcome in Patients with Hormone Receptor Positive, HER2-Normal Breast Cancer Treated with Adjuvant Chemohormonal Therapy. (2009) (4)
Concordance of local and central laboratory hormone and HER2 receptor status in ECOG 2197 (2007) (4)
Bernard Fisher, MD: In Memoriam (1918–2019) (2020) (4)
Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network (2020) (4)
Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer (2020) (3)
HER2-targeted therapies: how far we've come--and where we're headed. (2011) (3)
Updates in endocrine therapy for metastatic breast cancer (2021) (3)
Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer. (2010) (3)
Stomatitis-Related Pain in Women With Breast Cancer Undergoing Autologous Hematopoietic Stem Cell Transplant (2008) (3)
Small beginnings: do they matter? The importance of lymphovascular invasion in early breast cancer. (2009) (3)
Déjà vu for breast cancer two? (2004) (3)
Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer. (2014) (3)
204 – Breast Cancer and Benign Breast Disorders (2012) (3)
Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation? (2016) (3)
P2-12-02: Correlation between BMI and Clinical Outcome of Patients with Early Stage HER2+ Breast Cancer from the N9831 Clinical Trial. (2011) (3)
Long term follow‐up of women treated with 16‐week, dose‐intensive adjuvant chemotherapy for high risk breast carcinoma (1999) (3)
Diseases of the Breast Jay R. Harris, Marc E. Lippman, Monica Morrow, Samuel Hellman, eds. Philadelphia: Lippincott-Raven, 1996. 1047 pp., illus. $169. ISBN 0-397-51470-0 (1997) (3)
Increasing doses of cyclophosphamide suppress antigen-specific T helper-dependent immunity induced by a GM-CSF-secreting breast tumor vaccine (2008) (3)
25 Years Later: Endangered Species or Successful Evolution? (2011) (3)
Mechanisms of Chemoprotection against Aflatoxin-Induced Hepatocarcinogenesis by Oltipraz (1991) (3)
Follow-up Care for Cancer: Making the Benefits Equal the Cost (2000) (2)
Adjuvant ovarian suppression in premenopausal breast cancer | NOVA. The University of Newcastle's Digital Repository (2015) (2)
Extending Adjuvant Endocrine Therapy in Breast Cancer: Who, What, Why? (2019) (2)
Gene Expression Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast Cancer: Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor Pathway and Other Pathways. (2009) (2)
The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility (2020) (2)
New findings about endocrine therapy for breast cancer. (2003) (2)
“Take two”? The role of second opinions for breast biopsy specimens (2016) (2)
Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era. (2019) (2)
Association of a compact 13-gene VEGF signature with OS in E2100. (2012) (2)
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer (2003) (2)
Abstract P6-13-01: Local excision without radiation for ductal carcinoma in situ: 12-year results from the ECOG E5194 study (2015) (2)
A Phase I Toxicity and Feasibility Trial of Sequential Dose-Dense Induction Chemotherapy with Doxorubicin, Paclitaxel, and 5-Fluorouracil Followed by High Dose Consolidation for High-Risk Primary Breast Cancer (2002) (2)
Fifteen years of anti-HER2 therapy. (2013) (2)
Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2+BC): Results from the NCCTG adjuvant Intergroup trial N9831 (2008) (2)
How we maintain bone health in early-stage breast cancer patients on aromatase inhibitors. (2007) (2)
A pilot study evaluating surrogates of response to short-term vorinostat in women with newly diagnosed breast cancer. (2009) (2)
Management of Early Stage Breast Cancer (1997) (2)
A phase I study of diethylnorspermine (DENSPM) in previously treated patients with metastatic breast cancer (MBC) (2001) (2)
Screening for therapeutic targets of vorinostat by SILAC‐based proteomic analysis in human breast cancer cells (2010) (2)
What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer? (2009) (2)
Incident Cancer in Cancer Survivors-When Cancer Lurks in the Background. (2017) (1)
Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma (2019) (1)
Selection of Adjuvant Endocrine Therapy for Women with Breast Cancer in Menopausal Transition: Is It Simpler than We Thought? (2021) (1)
Optimal duration of trastuzumab for early HER2-positive breast cancer (2017) (1)
A prospective study of adjuvant anastrozole and gene promoter methylation in the contralateral breast of high-risk women (2008) (1)
Mitotic index to predict breast cancer recurrence after neoadjuvant systemic therapy. (2016) (1)
Conquering Metastatic Breast Cancer. (2016) (1)
Cancer Care at the Beginning of the COVID-19 Pandemic (2022) (1)
S28 Ovarian function suppression in the adjuvant program (2007) (1)
Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer (2010) (1)
Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER+ or to ER- disease? (2016) (1)
Protein Phosphatase 2A (PP2A) regulates estrogen receptor alpha (ER) expression through interaction with the ER promoter. (2004) (1)
Abstract P5-06-16: Histomorphometric measure of disorder of collagen fiber orientation is associated with risk of recurrence in ER+ breast cancers in ECOG-ACRIN E2197 and TCGA-BRCA (2020) (1)
116 Inhibition of p53-MDM2 pathway by novel boronic-chalcones (2004) (1)
Estrogen Receptor Status, Cell Cycling and Paclitaxel: Looking for a “Hormone”-ious Explanation (2004) (1)
Dose intensity for breast cancer: where do we go from here? (2001) (1)
Erratum: Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer (Journal of Biological Chemistry (2005) 280 (18302-18310)) (2005) (1)
Abstract 4877: Polyamine analogues modulate gene expression by inhibiting KDM1/LSD1 and altering chromatin structure in human breast cancer cells (2010) (1)
Therapeutic and Chemopreventive Actions of a Novel Polyamine Analog Against Breast Cancer (2002) (1)
Adjuvant chemotherapy of axillary lymph-node-positive breast cancer. (1992) (1)
P2-12-13: Topoisomerase 2 alpha (TOP2A) RNA Expression Provides Prognostic Information in Hormone Receptor Positive Breast Cancer That Is Complementary to a Simulated Algorithm for Recurrence Score. (2011) (1)
Relationship between taxane-induced neuropathy and clinical outcomes after adjuvant chemotherapy. (2011) (1)
Gonadotropin-Releasing Hormone (GnRH) Agonists for Fertility Preservation: Is POEMS the Final Verse? (2018) (1)
Abstract PD7-03: Investigating cortactin as a genetic driver of disease progression in invasive lobular carcinoma (2019) (1)
Adjuvant therapy of breast cancer (2004) (1)
PD05-03: Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831. (2011) (1)
negative Breast Cancer Cells α in Human ER-by DNA Methyltransferase and Histone Deacetylase Inhibition α Synergistic Activation of Functional Estrogen Receptor ( ER )-Updated Version (2001) (1)
Predictive utility of progesterone receptor (PR) and multigene expression in identifying benefit from adjuvant doxorubicin plus cyclophosphamide (AC) or docetaxel (AT) in intergroup trial E2197 (2008) (1)
Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation (2021) (1)
Abstract P2-11-10: Intra-tumor heterogeneity affects multi-gene test prognostic risk stratification (2013) (1)
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT (2022) (1)
Abstract P3-11-10: Response to subsequent therapies after failure to achieve pathologic complete response (pCR) after neo-adjuvant chemotherapy (NAC) in patients (pts) with triple negative breast cancer (TNBC) (2015) (1)
Abstract PD7-02: Novel human cell line xenograft models of ERα-positive metastatic invasive lobular breast carcinoma as pre-clinical platforms for validating candidate genetic drivers (2019) (1)
EDITORIAL DéjaVu for Breast Cancer Two (2004) (1)
Waging war on cancer Siddhartha Mukherjee The Emperor of All Maladies: A Biography of Cancer 2010 Simon & Schuster 1439107955 Pp 592. US$30·00. Watch a video of Siddhartha Mukherjee talking about this book at http://authors.simonandschuster.com/Siddhartha-Mukherje (2011) (1)
Adjuvant endocrine therapy: controversies and perspectives (2006) (1)
91 – Cancer of the Breast (2014) (1)
Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer? (2017) (1)
Abstract P5-07-01: Successful whole transcriptome analysis of 25-year-old breast tumor samples from the phase III trial SWOG-8814 by next generation sequencing (NGS): Standardized analytical methods for exploratory and validation studies (2016) (1)
Stage migration and micrometastases (2002) (1)
Abstract 1052: Synergy between inhibition of novel histone demethylase (LSD2) and DNA methyltransferase (DNMT) and histone deacetylase (HDAC) in modulating gene expression and inhibiting growth in human breast cancer cells (2012) (1)
Abstract 1385: New insights into the roles of histone lysine-specific demethylase 2 (LSD2) in breast cancer (2017) (1)
The Molecular Biology of Breast Cancer (2015) (1)
Estrogen Replacement Therapy in Breast Cancer Survivors (1995) (1)
Comprehensive 2D and 3D phenotypic characterization of human invasive lobular carcinoma cell lines (2018) (1)
Adjuvant chemo endocrine therapy (2014) (1)
Advances in Adjuvant and Neoadjuvant Therapy for Breast Cancer (2011) (1)
A digital health intervention to improve nutrition and physical activity in breast cancer survivors: Rationale and design of the Cook and Move for Your Life pilot and feasibility randomized controlled trial. (2022) (1)
Abstract P3-05-14: A neoadjuvant window trial of endocrine response in women with invasive lobular carcinoma (2016) (1)
Abstract P6-05-10: An international survey on invasive lobular breast cancer (ILC) reveals gaps in knowledge and top priority research areas (2023) (0)
Utilization of Magee equation 3 in ER-positive, HER2-negative/equivocal tumors to determine pathologic response to neoadjuvant therapy. (2016) (0)
A Phase II Study of the Polyamine Analog N,N- Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer (2003) (0)
Abstract 6231: Predictors of objectively-measured sedentary time during the COVID-19 pandemic among breast cancer survivors participating in a diet and physical activity intervention (2022) (0)
An Interview With AACR’s President-Elect (2015) (0)
Pathologic complete response (pCR) to preoperative sequential doxorubicin/cyclophosphamide (AC) and taxane (AC-T) or AC followed by paclitaxel and trastuzumab (AC-TH) in stage II-III HER2-positive breast cancer (2008) (0)
Phase I II, M ulticenter, D ouble-Blind, R andomized S tudy of L etrozole, a n A romatase I nhibitor, f or A dvanced B reast Cancer V ersus M egestrol A cetate (2001) (0)
Tracking 35 years of progress against breast cancer. (2008) (0)
Cost Burden Analysis of Ineffective Induction Chemotherapy in Elderly Patients with AML. (2009) (0)
Abstract P1-06-08: Independent validation of EarlyR gene signature in E2197: A randomized clinical trial comparing doxorubicin plus docetaxel to doxorubicin plus cyclophosphamide as adjuvant chemotherapy in breast cancer (2018) (0)
The challenges in translating present knowledge of the molecular biology of breast cancer into clinical use (2005) (0)
Abstract P2-09-08: c-MYC (MYC) Protein Expression and Associations with Trastuzumab Benefit in Early-Stage, HER2+ Breast Cancer in Context of the NCCTG Adjuvant Trial, N9831 (2010) (0)
Abstract 5700: Establishing candidate biomarkers for the pharmacodynamic action of sulforaphane in the breast (2010) (0)
Biology of breast cancer and its clinical implications. (1992) (0)
Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer (2011) (0)
Exploring Current Tests, Treatments in Breast Cancer Management (2018) (0)
Abstract CT509: Cook and Move for Your Life: A pilot study of an online intervention to improve diet and physical activity among breast cancer survivors (2022) (0)
Abstract P1-08-35: Stromal tumor infiltrating lymphocytes analysis by race and ethnicity in triple negative breast cancers from 2 phase III randomized adjuvant breast cancer trials: ECOG-ACRIN E2197 and E1199 (2022) (0)
Antigen Expression in Human Breast Cancer 1 (2003) (0)
Abstract 3648: Proteomic profiling of vorinostat in breast cancer (2010) (0)
The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831 (2015) (0)
Skeletal Complications of Malignancy Supplement to Cancer The Biology of Breast Carcinoma (2003) (0)
ESTROGEN REPLACEMENT THERAPY IN BREAST CANCER SURVIVORS. AUTHORS' REPLY (1995) (0)
Abstract 673: Targeting LSD1-HDACs crosstalk as a potential therapeutic strategy for triple negative breast cancer cells. (2013) (0)
Oral 1831-2 – Therapeutic actions of electrophilic nitroalkenes via inhibition of the NFκB pathway in triple negative breast cancer (2014) (0)
Gender differences in faculty rank and subspecialty choice in academic medical oncology. (2020) (0)
Handbook of Women's Health: Breast cancer screening (2001) (0)
Detection and functional analysis of estrogen receptor mutations (ESR1-mut) in patients with metastatic breast cancer (MBC). (2015) (0)
Abstract 5645: Associations between biomarkers and outcome in a patient cohort with invasive lobular carcinoma (2017) (0)
Carcinogen effects of glucocorticoid nuclear binding in rat liver (1976) (0)
Abstract A47: Establishing candidate biomarkers for the pharmacodynamic action of sulforaphane in the breast (2010) (0)
Advances in Brief Demethylation of the Estrogen Receptor Gene in Estrogen Receptor-negative Breast Cancer Cells Can Reactivate Estrogen Receptor Gene Expression 1 (1995) (0)
Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood (2018) (0)
Advances in Brief Induction of Programmed Cell Death in Human Breast Cancer Cells by an Unsymmetrically Alkylated Polyamine Analogue 1 (2006) (0)
Methylation-specific Polymerase Chain Reaction Mapping of ER Gene CpG Island Methylation by Updated (2006) (0)
ER Recruits Distinctive Corepressor Complexes Negative Breast Cancer Cells : Tamoxifen-Bound Reactivated − Restoration of Tamoxifen Sensitivity in Estrogen Receptor (2006) (0)
767 poster PARTIAL BREAST IRRADIATION WITH CONCURRENT DOSE DENSE DOXORUBICIN & CYCLOPHOSPHAMIDE: LATE TOXICITY & RECURRENCE (2011) (0)
Restrospective on the last quarter-century in medical oncology. (2011) (0)
Abstract P6-05-03: Exogenous steroid hormone exposure and the biology of lobular breast cancer (2020) (0)
Challenges and opportunities for physician-scientists in advancing cancer research. (2022) (0)
Reply to J.M. Guinebretiere and L. Arnould et al (2009) (0)
EDITORIALS Pesticides and Breast Cancer: Fact or Fad? (1997) (0)
Abstract GS2-03: Highly recurrent transcriptional remodeling events in advanced endocrine resistant ER-positive breast cancers (2018) (0)
Reply to C. Shah et al. (2016) (0)
Breast Cancer (2018) (0)
Abstract B104: Targeting Nrf2/ARE pathway by inhibition of HDAC in breast cancer prevention (2008) (0)
In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer. (2022) (0)
Abstract 3838: Functional crosstalk between histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) as a novel therapeutic target in triple-negative breast cancer cells (2015) (0)
Abstract A1-07: Identification of base pair mutations and structural rearrangements acquired in breast cancer metastases including a novel hyperactive ESR1-DAB2 fusion gene in hormone-resistant progression (2015) (0)
Abstract 1044: Breast cancer subtype-specific regulation of gene transcription and therapeutic response by functional crosstalk between LSD1 and HDACs (2012) (0)
WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines (2016) (0)
Estrogenic regulation of polyamine analogue cytotoxicity in human breast cancer cells (2005) (0)
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. (2023) (0)
Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists (2020) (0)
PG 11.01 Endocrine therapy for premenopausal women: type and duration (2015) (0)
NATIONAL INSTITUTES OF HEALTH National Cancer Institute Clinical Trials and Translational Research Advisory Committee CHAIR (2016) (0)
Human Breast Cancer following Estrogen Ablation Programmed Cell Death during Regression of the MCF-7 Updated Version (2006) (0)
The Schwartz/Billingsley/Wallner article reviewed (2000) (0)
APhase I-II Study of Combined Blockade of the ErbBReceptor Network with Trastuzumab and Gefitinib in Patients with HER 2 ( ErbB 2 )-OverexpressingMetastatic Breast Cancer (2008) (0)
Electrophilic Nitroalkenes Cause Degradation of NFκB RelA Protein in Triple Negative Breast Cancer Cells (2015) (0)
Electrophilic Nitroalkenes Inhibit Triple Negative Breast Cancer Metastasis (2016) (0)
PerspectivesofPostmenopausalBreastCancer SurvivorsonAdjuvantEndocrineTherapy-Related Symptoms (2014) (0)
Abstract S4-04: Tumor microenvironment of metastasis (TMEM) score is associated with early distant recurrence in hormone receptor (HR) positive, HER2-negative early stage breast cancer (ESBC) (2017) (0)
Commentary (Wolff/Davidson): Twenty Years of Systemic Therapy for Breast Cancer (2006) (0)
Abstract P2-03-17: Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2+ or HER2- metastatic breast cancer (2023) (0)
Advances in Brief Inhibition of Fatty Acid Synthesis Induces Programmed Cell Death in Human Breast Cancer Cells 1 (2006) (0)
Biology and prognostic factors of breast cancer. (1990) (0)
ANTIOXIDANTS AND ONCOGENESIS: ROLES IN CANCER CAUSATION AND PREVENTION (1993) (0)
Adjuvant Endocrine Therapy Trials in Premenopausal Patients (2003) (0)
Abstract PD7-07: Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer – new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814 (2017) (0)
Histone deacetylase inhibition reactivates the silenced estrogen receptor alpha gene and sensitizes ER-negative human breast cancer cells to Tamoxifen (2006) (0)
Searching for the IDEAL Duration of Adjuvant Endocrine Therapy. (2018) (0)
The molecular landscape of premenopausal breast cancer (2015) (0)
Abstract P6-08-02: Developing in vitro models of ductal carcinoma in situ from primary tissue (2016) (0)
Metastatic Breast Cancer: Tailored Endocrine Therapy for Premenopausal Women (2006) (0)
Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB 7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer (2011) (0)
A Digital Health Intervention to Improve Nutrition and Physical Activity in Breast Cancer Survivors: Rationale and Design of the Cook and Move for Your Life Pilot Randomized Controlled Trial (2022) (0)
Martin D. Abeloff, MD. (2008) (0)
New data on endocrine treatments (2003) (0)
Session 11: Adjuvant systemic treatment for the individual patient I: Endocrine therapies: New aspects for old treatments (2015) (0)
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models (2017) (0)
New data on adjuvant therapy for breast cancer (1999) (0)
The Mina/Sledge article reviewed (2006) (0)
Inhibition of Fatty Acid Synthesis Induces Programmed Cell Death in Human Breast Cancer Cells 1 (2006) (0)
Breast Cancer (2018) (0)
Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells (2011) (0)
Abstract P6-09-14: Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer (2017) (0)
Predictive Biomarkers and Personalized Medicine Impact of c-MYC Protein Expression on Outcome of Patients withEarly-StageHER 2 þ BreastCancerTreatedwithAdjuvant Trastuzumab NCCTG ( Alliance ) N 9831 (2013) (0)
Abstract 2841: Investigating drivers of disease progression in invasive lobular carcinoma (2017) (0)
Search worldwide , lifesciences literature (2012) (0)
Targeting a future without cancer Sincerely (2009) (0)
Reply to N. Magné et al (2009) (0)
Paradigm Shift in Adjuvant Treatment of Receptor Positive Premenopausal Breast Cancer Patients ? Not Yet ! (2003) (0)
Platelet Activation and Atherothrombosis (2008) (0)
Locoregional F ailure 1 0 Y ears A fter M astectomy and A djuvant C hemotherapy W ith o r W ithout T amoxifen Without I rradiation: E xperience o f t he E astern Cooperative O ncology G roup (1999) (0)
t reatment f or Breast Cancer: is t ime r eall y of the Essence? (2012) (0)
750 poster COSMETIC OUTCOME AFTER PARTIAL BREAST IRRADIATION WITH CONCURRENT CHEMOTHERAPY IN EARLY-STAGE BREAST CANCER (2011) (0)
Abstract 1993: Interaction between histone demethylase and deacetylase may mediate activity of HDAC inhibitors in human breast cancer cells (2011) (0)
A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer (2017) (0)
Abstract S1-03: Identification of base pair mutations and structural rearrangements acquired in breast cancer metastases including a novel hyperactive ESR1-DAB2 fusion gene specifically in hormone-resistant recurrence (2015) (0)
Breast cancer screening (2009) (0)
BOOKS: ‘The Death of Cancer’—by Vincent T. DeVita and Elizabeth DeVita-Raeburn (2016) (0)
Estrogens regulate production of specific growth factors in hormone-dependent human breast cancer. (1987) (0)
Abstract 5270: Disease subtype independent biomarkers of breast cancer prevention by withaferin a (2017) (0)
Effects of the Polyamine AnaloguesN-Ethyl-N-((cyclopropyl)methyl)- 4,8-diazaundecane andN-Ethyl-N-((cycloheptyl)methyl)-4,8- diazaundecane in Human Prostate Cancer Cells (2000) (0)
Molecular Biology of Breast Cancer Initiation and Progression Normal Breast Development (0)
Abstract 421: Comprehensive genomic analysis of metastatic breast cancers revealsESR1fusions as a recurrent mechanism of endocrine therapy resistance (2017) (0)
Programmed Cell Death in an Estrogen-independent Human Breast Cancer Cell Line , MDA-MB-4681 (2006) (0)
Breast Cancer Cells by Histone Deacetylase Inhibition in Human α Transcriptional Activation of Estrogen Receptor Updated (2000) (0)
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study (2020) (0)
Cancer Metastasis: Introduction to Clinical Research (2011) (0)
Abstract PD1-05: Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquiredERBB2amplifications and activating mutations (2017) (0)
Targeting Histone Abnormality in Triple-Negative Breast Cancer (2015) (0)
MultiparametricMagnetic Resonance Imaging , Spectroscopy and Multinuclear ( 23 Na ) Imaging Monitoring of Preoperative Chemotherapy for Locally Advanced Breast Cancer (2010) (0)
TITLE: Antineoplastic Efficacy of Novel Polyamine Analogues in Human Breast Cancer. PRINCIPAL INVESTIGATOR: (2006) (0)
Breast Cancer Primary Prevention: ‘SERM-Mounting’ Existing Obstacles and Future Directions (2012) (0)
Abstract S3-02: Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – Transcriptome expression analysis of the phase III trial SWOG-8814 (2016) (0)
Growth Inhibition of Hormone-responsive and -resistant Human Breast Cancer Cells in Culture by /V1,A^-BisiethyOspermine1 (2006) (0)
Investigating genetic drivers of disease progression in invasive lobular carcinoma (2018) (0)
Aflatoxin effects on glucocorticoid nuclear binding in rat liver (1975) (0)
Programmed Cell Death during Regression of the MCF-7 Human Breast Cancer following Estrogen Ablation 1 (2006) (0)
Electrophilic Nitro‐oleic Acid Inhibits Triple Negative Breast Cancer Cell Migration via Suppression of NF‐kB activity (2017) (0)
Abstract 3679: Modulation of estrogen depurinating DNA adduct by sulforaphane or KEAP1 knockdown in human breast epithelial cells. (2013) (0)
Evidence-Based AET in Women Before and After Menopause (2014) (0)
Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer (2020) (0)
Circling Back: Duration of Adjuvant Endocrine Therapy for Breast Cancer (2014) (0)
Selective Inhibition of Triple Negative Breast Cancer Cell Mobility and Viability by Nitro-Oleic Acid (2017) (0)
Endocrine-Related Cancer ( 2001 ) 8 115 – 127 DNA methylation in breast cancer (2001) (0)
Biology of breast cancer. (1991) (0)
The Changing Landscape of Targeted Breast Cancer Therapies (2020) (0)
Abstract 16746: Cardiovascular Disease Outcomes After Breast Cancer in Postmenopausal Women: Results From the Women’s Health Initiative (2015) (0)
The EstrogenReceptorCpG Island Is Methylatedin Most HematopoieticNeoplasms1 (1996) (0)
Metastatic breast cancer: a patient friendly approach with a new drug therapy (2001) (0)
Impact of Adjuvant Trastuzumab on Locoregional Failure Rates in the NCCTG N9831 (Alliance) Study (2019) (0)
Serendipity and purpose. (2016) (0)
Nancy Davidson, MD, Discusses Advancements in Breast Cancer (2019) (0)
Managing SCC of the Kidney (2019) (0)
Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001. (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Nancy E. Davidson?

Nancy E. Davidson is affiliated with the following schools:

Nancy E. Davidson's Academic­Influence.com Rankings

Nancy E. Davidson's Degrees

Why Is Nancy E. Davidson Influential?

Nancy E. Davidson's Published Works

Published Works

What Schools Are Affiliated With Nancy E. Davidson?

Nancy E. Davidson's AcademicInfluence.com Rankings